HR and breast carcinoma: The phase III INAVO120 trial demonstrated that inavolisib in combination with palbociclib and fulvestrant significantly improved survival outcomes compared with palbociclib plus fulvestrant [4] in PIK3CA-mutated, HR+/HER2- breast cancer patients with endocrine resistance.